Short Information | Command Security Corporation (NYSE:MOC)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 5,439 |
Total Actual Volume | 168,907 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 1 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 272 |
Average Short Percentage | 5.99% |
Is there a MOC Short Squeeze or Breakout about to happen?
See the MOC Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-21-2019 | $2.82 | $2.845 | $2.8499 | $2.82 | 51,128 | 2,065 | 4.04% |
02-20-2019 | $2.83 | $2.82 | $2.84 | $2.82 | 57,995 | 844 | 1.46% |
02-19-2019 | $2.77 | $2.81 | $2.81 | $2.77 | 1,680 | 27 | 1.61% |
02-15-2019 | $2.80 | $2.78 | $2.82 | $2.78 | 18,776 | 1 | 0.01% |
02-14-2019 | $2.82 | $2.78 | $2.82 | $2.78 | 1,649 | 40 | 2.43% |
02-13-2019 | $2.81 | $2.81 | $2.81 | $2.81 | 433 | 51 | 11.78% |
02-12-2019 | $2.80 | $2.8001 | $2.81 | $2.80 | 2,428 | 10 | 0.41% |
02-11-2019 | $2.8198 | $2.80 | $2.82 | $2.80 | 3,182 | 8 | 0.25% |
02-08-2019 | $2.80 | $2.79 | $2.81 | $2.79 | 534 | 1 | 0.19% |
02-05-2019 | $2.8231 | $2.80 | $2.8231 | $2.80 | 970 | 7 | 0.72% |
02-04-2019 | $2.81 | $2.81 | $2.81 | $2.81 | 3,425 | 6 | 0.18% |
01-31-2019 | $2.80 | $2.80 | $2.80 | $2.80 | 221 | 4 | 1.81% |
01-30-2019 | $N/A | $2.80 | $N/A | $N/A | 53 | 2 | 3.77% |
01-29-2019 | $2.8176 | $2.80 | $2.8176 | $2.80 | 392 | 122 | 31.12% |
01-24-2019 | $2.80 | $2.80 | $2.80 | $2.80 | 314 | 4 | 1.27% |
01-23-2019 | $2.7961 | $2.80 | $2.80 | $2.7961 | 727 | 16 | 2.2% |
01-22-2019 | $2.80 | $2.80 | $2.81 | $2.799 | 13,567 | 5 | 0.04% |
01-18-2019 | $2.80 | $2.80 | $2.80 | $2.80 | 2,552 | 25 | 0.98% |
01-17-2019 | $2.80 | $2.78 | $2.80 | $2.78 | 3,958 | 2,200 | 55.58% |
01-15-2019 | $2.78 | $2.79 | $2.79 | $2.78 | 4,923 | 1 | 0.02% |
News, Short Squeeze, Breakout and More Instantly...
Command Security Corporation Company Name:
MOC Stock Symbol:
NYSE Market:
Command Security Corporation Website:
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces part of the results of the work program consisting of eight drill holes for a total of 2,484 meters on the Gaboury project . Highlig...